Timeslot: Thursday, April 4, 2019 - 1:45pm to 3:45pm
Track: Immunomodulatory Biomaterials
Room: Chelan 5
Therapeutic modulation of the immune system is the emerging paradigm in medicine. For example, immunotherapy holds the promise of a cure for cancer, and is poised to expand into other therapeutic areas, such as inflammatory disorders, autoimmune diseases etc. However, several frontiers in immunotherapy remain to be explored. For example, can we design biomaterials for precise modulation/education of the immune system while avoiding toxicities? How can we locally active the immune response? Can we track the immune cells in real-time? The session will focus on engineered biomaterials for therapeutic immune modulation. Specifically, the session will cover topics ranging from biomaterials for delivery of immunomodulators and imaging agents, scaffolds, cell-based therapies etc. Several cutting edge immune engineering platforms will be included.
Abstracts will be available for download on April 3, 2019.
1:45:00 PM 265. Nanomaterial Vaccines to Overcome Poor Immune Response in Gut Microbiome-mediated Metabolic Syndrome, A. Singh*, M. Mosquera, S. Kim, H. Zhou, I. Brito; Cornell University, Ithaca, NY, USA
2:00:00 PM 266. Bridging the Gap Between Systemic Vaccine and Mucosal Immunity to Fight Cancer, S. Ferber*(1,2,3), U. von Andrian(3), R. Langer(2), N. Artzi(1,2,3,4); (1)Brigham and Women’s Hospital, Cambridge, MA, USA, (2)Massachusetts Institute of Technology, Cambridge, MA, USA, (3)Harvard Medical School, Boston, MA, USA, (4)Broad Institute of Har
2:15:00 PM 267. Enhanced T-cell Immunity in vivo Using Cell-instructive Scaffolds, N. Shah*(1), A. Mao(2), T.-Y. Shih(2), M. Kerr(1), D. Mooney(2), D. Scadden(2); (1)University of California, San Diego, La Jolla, CA, USA, (2)Harvard University, Cambridge, MA, USA
2:30:00 PM 268. The Biologic Scaffold Immune Microenvironment Inhibits Tumor Formation and Synergizes with Immunotherapy, M. Wolf*, J. Elisseeff; Johns Hopkins University, Baltimore, MD, USA
2:45:00 PM 269. Combinatorial, Microparticle-based Delivery of Immune Modulators Reprograms Dendritic Cell Phenotype and Promotes Remission of Collagen-induced Arthritis in Mice, R. Allen*(1), J. Lewis(1), S. Raychaudhuri(2), L. McKibbin(1), S. Chizari(1); (1)UC Davis, Davis, CA, USA, (2)UC Davis School of Medicine, Mather, CA, USA
3:00:00 PM 270. Immunomodulatory Biomaterials to Improve Allogeneic Islet Graft Survival in a Murine Diabetic Model, M. Coronel*(1), J. Weaver(1), M. Hunckler(1), E. Yolcu(2), H. Shirwan(2), A. Garcia(1); (1)Georgia Institute of Technology, Atlanta, GA, USA, (2)University of Louisville, Louisville, KY, USA
3:15:00 PM 271. Heparin-based IL-12 Complex Coacervate Inhibits B16F10 Melanoma Tumor Progression, M. Hwang*(1), R. Fecek(2), T. Qin(1), W. Storkus(2), Y. Wang(1); (1)Cornell University, Ithaca, NY, USA, (2)University of PIttsburgh, Pittsburgh, PA, USA
3:30:00 PM 272. A Bacterial Membrane Coated Nanoparticle in Combination with Radiation Therapy for In Situ Tumor Vaccination, M. Ye*(1), R. Patel(2), P. Carlson(2), B. Ma(1), Y. Wang(1), L. Zangl(2), I. Arthur(2), P. Sondel(2), Z. Morris(2), S. Gong(1); (1)University of Wisconsin–Madison, Madison, WI, USA, (2)University of Wisconsin School of Medicine and Public Health, Madison, WI, USA